Methods for inhibiting tie-2 kinase useful in the treatment of cancer

Patent metadata

Field	Value
Publication number	US-9457019-B2
Application number	US-201414535900-A
Country	US
Kind code	B2
Filing date	Nov 7, 2014
Priority date	Nov 7, 2013
Publication date	Oct 4, 2016
Grant date	Oct 4, 2016

Abstract

The present invention relates to methods of inhibiting TIE2 kinase useful in the treatment of tumor growth, invasiveness, intravazation, dissemination, metastasis, and immunosuppression. Specifically, the invention relates to methods of using 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea and salts thereof of Formula I.

First claim

The invention claimed is:

1. A method of blocking breast tumor growth, invasiveness, dissemination, metastasis, or increasing survival in breast cancer in patients comprising administering to a patient whose tumor microenvironment expresses TIE2 kinase in TIE2-expressing macrophages, an effective amount of a composition of Formula I

wherein
n is an integer from 0 to 7;
X is the basic radical of a pharmaceutically acceptable salt;
provided that when n is 0, the composition of Formula I is the parent free base;

in a dosing regimen sufficient to block TIE2 kinase in tumor microenvironment TIE2-expressing macrophages.

2. The method of claim 1 , wherein the dosing regimen is administered daily.

3. The method of claim 1 , wherein the dosing regimen is intermittent non-daily dosing, alternate daily dosing, every third daily dosing, twice weekly dosing, or once weekly dosing.

4. The method of claim 1 , wherein the composition of Formula I is used in combination with one or more agents taken from an anti-tubulin agent or an immunomodulatory agent.

5. The method of claim 1 , wherein the composition of Formula I is used in combination with paclitaxel.

6. The method of claim 1 , wherein the composition of Formula I is used in combination with paclitaxel protein-bound particles for injectable suspension.

7. The method of claim 1 , wherein the compound of Formula I is used in combination with eribulin.

8. A method of blocking breast cancer immunotolerance, comprising administering to a patient whose tumor microenvironment expresses TIE2 kinase in TIE2-expressing macrophages, an effective amount of a composition of Formula I

wherein
n is an integer from 0 to 7;
X is the basic radical of a pharmaceutically acceptable salt;
provided that when n is 0, the composition of Formula I is the parent free base,

in a dosing regimen sufficient to block TIE2 kinase in tumor microenvironment TIE2-expressing macrophages that mediate immunotolerance.

9. The method of claim 8 , wherein the dosing regimen is administered daily.

10. The method of claim 8 , wherein the dosing regimen is intermittent non-daily dosing, alternate daily dosing, every third daily dosing, twice weekly dosing, or once weekly dosing.

11. The method of claim 8 , wherein the composition of Formula I is used in combination with one or more agents taken from an anti-tubulin agent or an immunomodulatory agent.

12. The method of claim 8 , wherein the composition of Formula I is used in combination with paclitaxel.

13. The method of claim 8 , wherein the composition of Formula I is used in combination with paclitaxel protein-bound particles for injectable suspension.

14. The method of claim 8 , wherein the composition of Formula I is used in combination with eribulin.

15. The method of claim 8 , wherein the composition of Formula I is used in combination with an anti-CTLA-4 agent.

16. The method of claim 8 , wherein the composition of Formula I is used in combination with ipilimumab.

17. The method of claim 8 , wherein the composition of Formula I is used in combination with an anti-PD-1 agent.

18. The method of claim 8 , wherein the composition of Formula I is used in combination with lambrolizumab.

19. The method of claim 8 , wherein the composition of Formula I is used in combination with an anti-PD L-1 agent.

20. The method of claim 8 , wherein the composition of Formula I is used in combination with MPDL3280A.

21. A method of treating breast cancer patients in a neoadjuvant setting prior to surgical resection of tumor, comprising administering to a patient whose tumor microenvironment expresses TIE2 kinase in TIE2-expressing macrophages, an effective amount of the composition of Formula I

wherein
n is an integer from 0 to 7;
X is the basic radical of a pharmaceutically acceptable salt;
provided that when n is 0, the composition of Formula I is the parent free base,

prior to surgical resection of tumor in a dosing regimen sufficient to block TIE2 kinase in tumor microenvironment TIE2-expressing macrophages.

22. The method of claim 21 , wherein the dosing regimen is administered daily.

23. The method of claim 21 , wherein the dosing regimen is intermittent non-daily dosing, alternate daily dosing, every third daily dosing, twice weekly dosing, or once weekly dosing.

24. The method of claim 21 , wherein the composition of Formula I is used in combination with paclitaxel.

25. The method of claim 21 , wherein the composition of Formula I is used in combination with paclitaxel protein-bound particles for injectable suspension.

26. The method of claim 21 , wherein the composition of Formula I is used in combination with eribulin.

27. The method of claim 21 , wherein the composition of Formula I is used in combination with an anti-CTLA-4 agent.

28. The method of claim 21 , wherein the composition of Formula I is used in combination with ipilimumab.

29. The method of claim 21 , wherein the composition of Formula I is used in combination with an anti-PD-1 agent.

30. The method of claim 21 , wherein the composition of Formula I is used in combination with lambrolizumab.

31. The method of claim 21 , wherein the composition of Formula I is used in combination with an anti-PD L-1 agent.

32. The method of claim 21 , wherein the composition of Formula I is used in combination with MPDL3280A.

33. A method of treating cancer, comprising administering to a patient whose tumors express tunica interna endothelial cell kinase-2 (TIE2 kinase), an effective amount of a composition of Formula I:

wherein
n is an integer from 0 to 7;
X is the basic radical of a pharmaceutically acceptable salt;
provided that when n is 0, the composition of Formula I is the parent free base,
wherein the patient expresses tunica interna endothelial cell kinase-2 (TIE2 kinase).

34. The method of claim 33 , wherein the composition of Formula I is administered in combination with one or more other agents.

35. The method of claim 33 , wherein the composition of Formula I is administered daily.

36. The method of claim 33 , wherein the composition of Formula I is administered intermittent non-daily.

37. The method of claim 33 , wherein the treatment comprises reducing one or more of primary tumor growth, tumor invasiveness, cancer intravasation, cancer dissemination, metastasis, and tumor immunotolerance.

38. The method of claim 34 , wherein the other agent is one or more of paclitaxel, paclitaxel protein-bound particles for injectable suspension, eribulin, docetaxel, ixabepilone, vincristine, vinorelbine, cisplatin, carboplatin, oxaliplatin, cyclophosphamide, ifosfamide, temozolomide, doxorubicin, pegylated liposomal doxorubicin, daunorubicin, idarubicin, epirubicin, 5-fluorouraci

Assignees

• Deciphera Pharmaceuticals Llc

Inventors

• Flynn Daniel L
• Kaufman Michael D
• Smith Bryan D
• Rudoltz Marc

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K47/64

  Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K31/351

  not condensed with another ring · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title